WALTHAM, Mass. - Invivyd, Inc. (NASDAQ:IVVD), a biopharmaceutical company, announced interim exploratory data from its Phase 3 CANOPY clinical trial regarding VYD222, an investigational monoclonal antibody for COVID-19 pre-exposure prophylaxis.
The trial aims to understand the relationship between serum virus neutralizing antibody (sVNA) titers and clinical efficacy, particularly in individuals with prior immunity from vaccination or infection.
The company shared an update on symptomatic COVID-19 events through Day 90, following an initial report in December 2023 that suggested a potential signal of clinical protection. The current findings indicate a 0.3% occurrence of symptomatic COVID-19 in the VYD222 group versus 5% in the placebo group within the non-immunocompromised cohort. For the immunocompromised cohort, the occurrence was 1% with VYD222.
These interim results are not the primary focus of the CANOPY trial but may inform future research and development. Invivyd plans to present a more comprehensive analysis at Day 180, including a comparison between measured and calculated sVNA titers and their correlation with clinical outcomes.
VYD222 is a neutralizing, half-life extended monoclonal antibody candidate designed for broad activity against various SARS-CoV-2 variants. It is based on adintrevimab, another of Invivyd's investigational antibodies, which has shown promising results in previous clinical trials.
Invivyd's mission is to provide antibody-based therapies for serious viral diseases, with COVID-19 as the starting point. The company's proprietary INVYMAB™ platform combines viral surveillance, predictive modeling, and advanced antibody engineering to develop a pipeline of potential treatments.
The information in this article is based on a press release statement from Invivyd.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.